Business Description
Ashland Inc. operates as a global supplier of specialized chemicals and additives. Its business activities are structured into four main divisions: Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents. The Life Sciences segment delivers pharmaceutical formulations, encompassing controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and binding agents for tablets. It also offers nutritional compounds like thickeners, stabilizers, emulsifiers, and various additives, alongside nutraceutical items designed for weight management, joint comfort, gastrointestinal health, sports nutrition, and general well-being. Additionally, this division provides custom formulation services, toll processing, and particle engineering expertise. The Personal Care & Household division manufactures a diverse array of naturally derived, biodegradable, and high-performance ingredients for personal care products. Its offerings extend to solutions for oral hygiene, such as toothpastes, mouthwashes, denture cleansers, and general dental care. For household applications, it supplies nature-sourced rheology modifiers, biodegradable wetting agents for surfaces, advanced encapsulants, and specialized polymers. The Specialty Additives segment's portfolio includes rheology modifiers, agents for foam control, surfactants, wetting agents, pH neutralizers, and advanced ceramic materials, which find application in catalytic converters, environmental filters, components for ceramic capacitors, plasma display panels, and solar cells. Furthermore, it supplies ingredients for textile printing, thermoplastic metals, and alloys utilized in welding processes. The Intermediates and Solvents division is responsible for producing 1,4 butanediol and its associated derivatives, notably n-methylpyrrolidone. Ashland's diverse product portfolio serves clientele across numerous consumer and industrial sectors, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceuticals. The company, previously known as Ashland Global Holdings Inc., was established in Wilmington, Delaware, in 1924.
Business History
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -18.37
Total Equity: $1.90B
Shares: 46,000,000
Total Debt: $1.49B
Cash: $215.00M
EBITDA: -$509.00M
Total Debt: $1.49B
Cash: $215.00M
Revenue: $1.82B
Shares: 46,000,000
Revenue: $1.82B
Revenue: $1.82B
Revenue: $1.82B
Total Equity: $1.90B
Tax Rate: -1.6%
Equity: $1.90B
Total Debt: $1.49B
Cash: $215.00M
Current Liabilities: $423.00M
Long-Term Debt: $1.47B
Total Debt: $1.49B
Total Equity: $1.90B
Shares: 46,000,000
Shares: 46,000,000
CapEx: -$98.00M
Shares: 46,000,000
Stock Price: $63.94
Net Income: -$845.00M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 6:54pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.1B | $2.4B | $2.2B | $2.1B | $1.8B |
| Cost of Revenue | $1.4B | $1.6B | $1.5B | $1.5B | $1.3B |
| Gross Profit | $670.0M | $830.0M | $668.0M | $618.0M | $549.0M |
| Operating Expenses | $478.0M | $497.0M | $496.0M | $644.0M | $1.3B |
| Operating Income | $192.0M | $333.0M | $172.0M | -$26.0M | -$775.0M |
| Net Income | $220.0M | $927.0M | $178.0M | $169.0M | -$845.0M |
| EBITDA | $448.0M | $509.0M | $457.0M | $303.0M | -$509.0M |
| EPS | $2.85 | $17.17 | $3.36 | $3.45 | $-18.37 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 6:54pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $210.0M | $646.0M | $417.0M | $300.0M | $215.0M |
| Total Current Assets | $1.7B | $1.8B | $1.5B | $1.2B | $1.2B |
| Total Assets | $6.6B | $6.2B | $5.9B | $5.6B | $4.6B |
| Current Liabilities | $934.0M | $553.0M | $456.0M | $490.0M | $423.0M |
| Long-Term Debt | $1.6B | $1.3B | $1.3B | $1.3B | $1.5B |
| Total Liabilities | $3.9B | $3.0B | $2.8B | $2.8B | $2.7B |
| Total Equity | $2.8B | $3.2B | $3.1B | $2.9B | $1.9B |
| Retained Earnings | $2.8B | $3.7B | $3.6B | $3.3B | $2.3B |
Cash Flow (Annual)
Last updated: Jun 21, 2026 6:54pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $560.0M | -$213.0M | $243.0M | $411.0M | $94.0M |
| Capital Expenditure | -$105.0M | -$113.0M | -$170.0M | -$137.0M | -$98.0M |
| Free Cash Flow | $455.0M | -$326.0M | $73.0M | $274.0M | -$4.0M |
| Acquisitions (net) | -$304.0M | $0 | $0 | $26.0M | $16.0M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$450.0M | -$200.0M | -$300.0M | -$380.0M | -$100.0M |
| Net Change in Cash | -$244.0M | $436.0M | -$229.0M | -$117.0M | -$85.0M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 8:28am (28m ago)| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue |
$1.8B $1.8B – $1.8B
|
$1.9B $1.8B – $1.9B
|
$1.9B $1.9B – $2.0B
|
$2.0B $2.0B – $2.0B
|
| EBITDA |
$182.0M $181.0M – $183.0M
|
$184.3M $183.3M – $186.3M
|
$192.1M $188.1M – $196.1M
|
$198.7M $198.5M – $199.0M
|
| Net Income |
$163.2M $157.8M – $168.6M
|
$161.2M $144.3M – $178.0M
|
$192.1M $167.4M – $216.9M
|
$222.8M $187.8M – $257.8M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 6:54pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +13.3% | -8.4% | -3.6% | -13.7% |
| Gross Profit Growth | +23.9% | -19.5% | -7.5% | -11.2% |
| Operating Income Growth | +73.4% | -48.3% | -115.1% | -2,880.8% |
| Net Income Growth | +321.4% | -80.8% | -5.1% | -600.0% |
| EBITDA Growth | +13.6% | -10.2% | -33.7% | -268.0% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 8:28am (28m ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-15 | LOY BERTRAND | A-Award | 1,741.00 | $0.00 | $0 |
| 2026-05-15 | LOY BERTRAND | 0.00 | $0.00 | $0 | |
| 2026-05-08 | MINICUCCI JAMES P. | M-Exempt | 4,310.00 | $55.01 | $237,093 |
| 2026-05-08 | MINICUCCI JAMES P. | F-InKind | 1,346.00 | $55.01 | $74,043 |
| 2026-05-08 | MINICUCCI JAMES P. | M-Exempt | 4,310.00 | $0.00 | $0 |
| 2026-03-31 | Chattopadhyay Sanat | A-Award | 258.00 | $0.00 | $0 |
| 2026-03-31 | Bishop Steven D | A-Award | 450.00 | $0.00 | $0 |
| 2026-02-06 | NOVO GUILLERMO | A-Award | 32,096.00 | $0.00 | $0 |
| 2026-01-20 | Harrison Suzan F. | A-Award | 2,449.00 | $0.00 | $0 |
| 2026-01-20 | Kulkarni Ashish K | A-Award | 2,449.00 | $0.00 | $0 |
| 2026-01-21 | Kulkarni Ashish K | M-Exempt | 2,113.00 | $0.00 | $0 |
| 2026-01-21 | Kulkarni Ashish K | M-Exempt | 2,113.00 | $0.00 | $0 |
| 2026-01-20 | Bishop Steven D | A-Award | 2,449.00 | $0.00 | $0 |
| 2026-01-20 | Chattopadhyay Sanat | A-Award | 2,449.00 | $0.00 | $0 |
| 2026-01-20 | MAIN SUE | A-Award | 2,449.00 | $0.00 | $0 |
| 2026-01-20 | Peribere Jerome A | A-Award | 2,449.00 | $0.00 | $0 |
| 2026-01-20 | Tozier Scott | A-Award | 2,449.00 | $0.00 | $0 |
| 2025-12-31 | Bishop Steven D | A-Award | 426.00 | $0.00 | $0 |
| 2025-12-31 | Chattopadhyay Sanat | A-Award | 245.00 | $0.00 | $0 |
| 2025-11-19 | Assis Alessandra Faccin | A-Award | 13,807.00 | $50.58 | $698,358 |
Dividend History (Last 20)
Last updated: Jun 21, 2026 6:54pm (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-01 | $0.42 | 2026-05-05 | 2026-06-01 | 2026-06-15 |
| 2026-02-27 | $0.42 | 2026-01-19 | 2026-03-01 | 2026-03-15 |
| 2025-12-01 | $0.42 | 2025-11-19 | 2025-12-01 | 2025-12-15 |
| 2025-08-29 | $0.42 | 2025-08-08 | 2025-09-01 | 2025-09-15 |
| 2025-05-30 | $0.42 | 2025-05-06 | 2025-06-01 | 2025-06-15 |
| 2025-02-28 | $0.41 | 2025-01-20 | 2025-03-01 | 2025-03-15 |
| 2024-11-29 | $0.41 | 2024-11-14 | 2024-12-01 | 2024-12-15 |
| 2024-08-30 | $0.41 | 2024-08-09 | 2024-09-01 | 2024-09-15 |
| 2024-05-31 | $0.41 | 2024-05-07 | 2024-06-01 | 2024-06-15 |
| 2024-02-29 | $0.39 | 2024-01-22 | 2024-03-01 | 2024-03-15 |
| 2023-11-30 | $0.39 | 2023-11-13 | 2023-12-01 | 2023-12-15 |
| 2023-08-31 | $0.39 | 2023-08-14 | 2023-09-01 | 2023-09-15 |
| 2023-05-31 | $0.39 | 2023-05-11 | 2023-06-01 | 2023-06-15 |
| 2023-02-28 | $0.34 | 2023-01-23 | 2023-03-01 | 2023-03-15 |
| 2022-11-30 | $0.34 | 2022-11-18 | 2022-12-01 | 2022-12-15 |
| 2022-08-31 | $0.34 | 2022-08-05 | 2022-09-01 | 2022-09-15 |
| 2022-05-31 | $0.34 | 2022-05-24 | 2022-06-01 | 2022-06-15 |
| 2022-02-28 | $0.30 | 2022-01-25 | 2022-03-01 | 2022-03-15 |
| 2021-11-30 | $0.30 | 2021-11-22 | 2021-12-01 | 2021-12-15 |
| 2021-08-31 | $0.30 | 2021-08-05 | 2021-09-01 | 2021-09-15 |
Narrative Economics
market-narrative step).